Recombinant Mouse Adcy1 protein, His & T7-tagged
Welcome! For price inquiries, please feel free to contact us through the form below. We will get back to you as soon as possible.
|Cat.No. :||Adcy1-6842M Optional Service: Optional requirements on this protein|
|Product Overview :||Recombinant Mouse Adcy1 aa. (Ile303~Ser569 (Accession # O88444)) fused with N-terminal His & T7 tag was produced in E. coli cells.|
|Source :||E. coli|
|Tag :||His & T7|
|Form :||Freeze-dried powder|
|Molecular Mass :||Predicted Molecular Mass: 34.0kDa.|
|Protein length :||Ile303~Ser569 (Accession # O88444)|
|Endotoxin :||<1.0EU per 1ug (determined by the LAL method)|
|Characteristic :||The isoelectric point is 8.7.|
|Applications :||SDS-PAGE; WB; ELISA; IP.|
|Stability :||The thermal stability is described by the loss rate of the target protein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. (Referring from China Biological Products Standard, which was calculated by the Arrhenius equation.) The loss of this protein is less than 5% within the expiration date under appropriate storage condition.|
|Storage :||Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.|
|Storage buffer :||Supplied as lyophilized form in PBS, pH7.4, containing 5% trehalose, 0.01% sarcosyl.|
|Reconstitution :||Reconstitute in sterile PBS, pH7.2-pH7.4.|
|Gene Name :||Adcy1 adenylate cyclase 1 [ Mus musculus (house mouse) ]|
|Official Symbol :||Adcy1|
|Synonyms :||AC1; brl; I-AC; mKIAA4070; D11Bwg1392e; ATP pyrophosphate-lyase 1; Ca(2+)/calmodulin-activated adenylyl cyclase; adenylate cyclase type I; adenylyl cyclase 1; barrelless; adenylate cyclase type 1|
|Gene ID :||432530|
|mRNA Refseq :||NM_009622.1|
|Protein Refseq :||NP_033752.1|
|UniProt ID :||O88444|
◆ Recombinant Protein
|ADCY1-2429H||Recombinant Human ADCY1 Protein, His (Fc)-Avi-tagged||+Inquiry|
|ADCY1-336M||Recombinant Mouse ADCY1 Protein, His (Fc)-Avi-tagged||+Inquiry|
|ADCY1-6841H||Recombinant Human ADCY1 protein, His & T7-tagged||+Inquiry|
|ADCY1-3170B||Recombinant Bovine ADCY1, GST-tagged||+Inquiry|
|ADCY1-1342M||Recombinant Mouse ADCY1 Protein||+Inquiry|
See All Adcy1 Recombinant Protein
Please Contact Us for an Inquiry
Adcy1 protein activity is regulated by various mechanisms, including post-translational modifications such as phosphorylation and by interaction with other proteins that can modulate its activity. Adcy1 protein is also subject to regulation by various extracellular signals that activate or inhibit cAMP signaling, including hormones and neurotransmitters.
Currently, there are no clinical trials specifically focused on Adcy1 protein. However, some clinical trials are investigating the potential therapeutic effects of drugs that target cAMP signaling, which may indirectly affect Adcy1 activity.
There are several ways to target Adcy1 protein for therapeutic use. One approach is to use small molecule inhibitors to block the activity of Adcy1. Another approach is to use gene therapy to increase or decrease the expression of Adcy1 in specific cells or tissues.
Adcy1 protein has been implicated in a variety of physiological and pathophysiological processes, suggesting that it may have therapeutic potential in a number of conditions. For example, manipulating the activity of Adcy1 could be useful in the treatment of various diseases, such as inflammatory disorders, metabolic disorders, and neurological disorders.
Dysregulation of cAMP signaling, which is regulated by Adcy1 protein, has been implicated in the development and progression of various types of cancer. For example, decreased Adcy1 expression has been associated with the progression of colorectal cancer. However, more research is needed to fully understand the role of Adcy1 protein in cancer and to evaluate its potential use as a therapeutic target.
Adcy1 protein has been shown to play a role in the regulation of synaptic plasticity, which is important for learning and memory. However, more research is needed to fully understand the effects of Adcy1 protein on cognitive function and to determine whether Adcy1-targeted therapies could be useful in treating cognitive disorders such as Alzheimer's disease and other dementias.
There are currently no drugs approved for therapeutic use that specifically target Adcy1 protein. However, several drugs that indirectly affect Adcy1 and cAMP signaling, such as beta-blockers and phosphodiesterase inhibitors, are already in clinical use for the treatment of cardiovascular and respiratory disorders.
Adcy1 protein plays a role in the regulation of cyclic AMP (cAMP) signaling, which is involved in many cellular processes. Therapeutic applications of Adcy1 protein may include the treatment of disorders related to abnormal cAMP signaling, such as heart disease, diabetes, and certain types of cancer.
Adcy1 protein is being studied in various research settings to better understand its role in cAMP signaling and cellular processes. This includes studies using cell-based models, animal models, and genetic analyses of patients with disorders related to cAMP signaling. Researchers are also exploring the potential therapeutic effects of Adcy1-targeted drugs on various conditions.
As Adcy1 protein is involved in many cellular processes, targeted therapy for Adcy1 may have off-target effects on other cellular functions. The potential side effects of Adcy1-targeted therapies are not yet fully understood as research in this area is ongoing. However, as with any targeted therapy, potential adverse effects will need to be thoroughly evaluated before clinical use.
Adcy1 protein is an enzyme composed of a single protein chain that forms a complex three-dimensional structure. The protein contains multiple domains, including a C1 domain involved in signaling lipids, a catalytic domain that mediates the production of cAMP, and a regulatory domain that modulates its activity in response to various stimuli.
Adcy1 protein may be a target for drug development aimed at modulating cAMP signaling. However, the development of Adcy1-targeted drugs is still in the early stages of research and more work is needed to fully understand the role of Adcy1 protein in disease and to identify potential drug targets.
Potential advantages of targeting Adcy1 protein include the specificity of the therapy, as Adcy1 is not involved in many essential cellular processes, and the potential for personalized medicine, as the activity of Adcy1 can vary depending on the individual and the disease state. However, potential disadvantages include the risk of off-target effects on other cellular processes and the possibility of resistance to therapy developing over time.
Required fields are marked with *×
Required fields are marked with *×
Apply For A Coupon
Easy access to products and services you need from our library via powerful searching tools.